Cipla's Q2 profit misses estimates as US business struggles, shares tumble 5%
· Business · Reuters, Investing.com
Cipla's consolidated net profit fell 19.5% to ₹827.2 crore for Q2 FY26, missing analyst estimates, driven by a sharp decline in its US business performance. The company's India business maintained stable growth, but the US segment saw significant headwinds that dragged overall results. Cipla's total revenue declined to ₹5,955 crore from ₹6,403 crore in the year-ago period. The stock dropped over 5% in early trade following the earnings miss, reflecting investor concerns about the US market outlook.
Why it matters
Cipla's profit miss directly affects Indian shareholders and employees as the company grapples with underperformance in its key international market, the United States. The US business slump threatens Cipla's growth trajectory in its largest overseas market, potentially impacting future expansion plans and stock valuation for India's fifth-largest pharmaceutical company.
Read the original report — Reuters
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.